ERBB2 and non-small cell lung carcinoma: The 2021 Chinese Society of Clinical Oncology (CSCO) guidelines provided a Grade III recommendation for pyrotinib, a small-molecule tyrosine kinase inhibitor, as a later-line treatment for HER2-mutant advanced NSCLC (Wang et al., 2022).